Literature DB >> 23687938

Serum brain biomarker level, neurocognitive performance, and self-reported symptom changes in soldiers repeatedly exposed to low-level blast: a breacher pilot study.

Charmaine M Tate1, Kevin K W Wang, Stephanie Eonta, Yang Zhang, Walter Carr, Frank C Tortella, Ronald L Hayes, Gary H Kamimori.   

Abstract

"Breachers" are a unique military and law enforcement population because they are routinely exposed to low-level blast (LLB) during training and operations. This repeated exposure has been associated with symptoms similar to that of sports concussion. This study examined effects of repeated exposure to LLB during an explosive entry course. Twenty-one members of the New Zealand Defence Force volunteered for this study. Serum samples, neurocognitive performance, and self-reported symptoms were periodically measured before, during, and after a 2-week course. Serum concentrations of three biomarkers, ubiquitin C-terminal hydrolase-L1, αII-spectrin breakdown product, and glial fibrillary acidic protein, were determined with sandwich enzyme-linked immunosorbent assays, and rank scores were derived using the area under the curve (relative to baseline) for each subject. Neurocognitive performance was measured with a computer-based test battery, and symptoms were assessed by paper-based inventory. There was a significant relationship (p<0.05) between composite biomarker and neurocognitive performance and between neurocognitive performance and symptoms. The individuals with the five highest (Top 5) and lowest (Bottom 5) composite biomarker scores were identified and compared using Wilcoxon's rank-sum test. The Top 5 had significantly longer reaction times and lower percent correct on neurocognitive performance and an increase in symptom reporting. The difference between individuals expressing the highest biomarker load during breacher training (Top 5) and those with the lowest biomarker load (Bottom 5) is reflected in neurocognitive performance deficits and self-reported symptoms. This suggests a measureable degree of brain perturbation linked to LLB exposure. Follow-up studies are underway to expand upon these results.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23687938     DOI: 10.1089/neu.2012.2683

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  44 in total

1.  Structural and biochemical abnormalities in the absence of acute deficits in mild primary blast-induced head trauma.

Authors:  Michael K Walls; Nicholas Race; Lingxing Zheng; Sasha M Vega-Alvarez; Glen Acosta; Jonghyuck Park; Riyi Shi
Journal:  J Neurosurg       Date:  2015-08-21       Impact factor: 5.115

Review 2.  Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker.

Authors:  Zhihui Yang; Kevin K W Wang
Journal:  Trends Neurosci       Date:  2015-05-11       Impact factor: 13.837

3.  Primary blast injury causes cognitive impairments and hippocampal circuit alterations.

Authors:  Matthew Beamer; Shanti R Tummala; David Gullotti; Catherine Kopil; Samuel Gorka; Cameron R Dale Bass; Barclay Morrison; Akiva S Cohen; David F Meaney
Journal:  Exp Neurol       Date:  2016-05-28       Impact factor: 5.330

4.  Clinical and imaging assessment of acute combat mild traumatic brain injury in Afghanistan.

Authors:  Octavian Adam; Christine L Mac Donald; Dennis Rivet; John Ritter; Todd May; Maria Barefield; Josh Duckworth; Donald LaBarge; Dean Asher; Benjamin Drinkwine; Yvette Woods; Michael Connor; David L Brody
Journal:  Neurology       Date:  2015-06-24       Impact factor: 9.910

5.  Neurotransmitter Systems in a Mild Blast Traumatic Brain Injury Model: Catecholamines and Serotonin.

Authors:  Lizan Kawa; Ulf P Arborelius; Takashi Yoshitake; Jan Kehr; Tomas Hökfelt; Mårten Risling; Denes Agoston
Journal:  J Neurotrauma       Date:  2015-04-01       Impact factor: 5.269

Review 6.  Chronic neurodegeneration after traumatic brain injury: Alzheimer disease, chronic traumatic encephalopathy, or persistent neuroinflammation?

Authors:  Alan I Faden; David J Loane
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

7.  Characterization and standardization of multiassay platforms for four commonly studied traumatic brain injury protein biomarkers: a TBI Endpoints Development Study.

Authors:  George Anis Sarkis; Tian Zhu; Zhihui Yang; Xue Li; Yuan Shi; Richard Rubenstein; Richard A Yost; Geoffrey T Manley; Kevin K Wang
Journal:  Biomark Med       Date:  2021-10-22       Impact factor: 2.851

8.  Chronic Effects of Breaching Blast Exposure on Sensory Organization and Postural Limits of Stability.

Authors:  F J Haran; Cris Zampieri; Eric M Wassermann; Elena Polejaeva; Kristine C Dell; Matthew L LoPresti; James R Stone; Stephen T Ahlers; Walter Carr
Journal:  J Occup Environ Med       Date:  2021-11-01       Impact factor: 2.162

9.  Coordinating Global Multi-Site Studies of Military-Relevant Traumatic Brain Injury: Opportunities, Challenges, and Harmonization Guidelines.

Authors:  David F Tate; Emily L Dennis; John T Adams; Maheen M Adamson; Heather G Belanger; Erin D Bigler; Heather C Bouchard; Alexandra L Clark; Lisa M Delano-Wood; Seth G Disner; Blessen C Eapen; Carol E Franz; Elbert Geuze; Naomi J Goodrich-Hunsaker; Kihwan Han; Jasmeet P Hayes; Sidney R Hinds; Cooper B Hodges; Elizabeth S Hovenden; Andrei Irimia; Kimbra Kenney; Inga K Koerte; William S Kremen; Harvey S Levin; Hannah M Lindsey; Rajendra A Morey; Mary R Newsome; John Ollinger; Mary Jo Pugh; Randall S Scheibel; Martha E Shenton; Danielle R Sullivan; Brian A Taylor; Maya Troyanskaya; Carmen Velez; Benjamin Sc Wade; Xin Wang; Ashley L Ware; Ross Zafonte; Paul M Thompson; Elisabeth A Wilde
Journal:  Brain Imaging Behav       Date:  2021-01-07       Impact factor: 3.978

10.  Sequelae of Blast Events in Iraq and Afghanistan War Veterans using the Salisbury Blast Interview: A CENC Study.

Authors:  Jared A Rowland; Sarah L Martindale; Kayla M Spengler; Robert D Shura; Katherine H Taber
Journal:  Brain Inj       Date:  2020-02-25       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.